- Home
- VERB vs KPRX Comparison
VERB vs KPRX Comparison
Compare VERB & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERB
- KPRX
- Stock Information
- Founded
- VERB 2014
- KPRX 1998
- Country
- VERB United States
- KPRX United States
- Employees
- VERB N/A
- KPRX N/A
- Industry
- VERB Other Consumer Services
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- VERB Consumer Discretionary
- KPRX Health Care
- Exchange
- VERB Nasdaq
- KPRX Nasdaq
- Market Cap
- VERB 9.6M
- KPRX 9.1M
- IPO Year
- VERB N/A
- KPRX N/A
- Fundamental
- Price
- VERB N/A
- KPRX $2.85
- Analyst Decision
- VERB Strong Buy
- KPRX Strong Buy
- Analyst Count
- VERB 1
- KPRX 1
- Target Price
- VERB $62.00
- KPRX $10.00
- AVG Volume (30 Days)
- VERB 26.8K
- KPRX 86.9K
- Earning Date
- VERB 08-13-2025
- KPRX 08-08-2025
- Dividend Yield
- VERB N/A
- KPRX N/A
- EPS Growth
- VERB N/A
- KPRX N/A
- EPS
- VERB N/A
- KPRX N/A
- Revenue
- VERB $2,193,000.00
- KPRX $20,000.00
- Revenue This Year
- VERB $526.82
- KPRX N/A
- Revenue Next Year
- VERB $45.45
- KPRX N/A
- P/E Ratio
- VERB N/A
- KPRX N/A
- Revenue Growth
- VERB 3125.00
- KPRX N/A
- 52 Week Low
- VERB $3.81
- KPRX $2.51
- 52 Week High
- VERB $27.14
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- VERB 62.46
- KPRX 40.98
- Support Level
- VERB $6.61
- KPRX $2.68
- Resistance Level
- VERB $7.32
- KPRX $2.94
- Average True Range (ATR)
- VERB 0.58
- KPRX 0.16
- MACD
- VERB -0.00
- KPRX -0.03
- Stochastic Oscillator
- VERB 91.94
- KPRX 23.99
About VERB Verb Technology Company Inc.
Verb Technology Co Inc leader in interactive video-based sales applications, transforms how businesses attract and engage customers. VERB's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.